{
    "eid": "2-s2.0-85086918941",
    "title": "Dengue vaccine: a key for prevention",
    "cover-date": "2020-06-02",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Molecular Medicine",
            "@code": "1313",
            "@abbrev": "BIOC"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "dengue vaccine development",
        "dengue vaccines in the clinical trial pipeline",
        "Global threat of dengue",
        "licensed dengue vaccine"
    ],
    "authors": [
        "Usa Thisyakorn",
        "Terapong Tantawichien"
    ],
    "citedby-count": 2,
    "ref-count": 50,
    "ref-list": [
        "Dengue: global threat",
        "Urbanisation and infectious diseases in a globalized world",
        "The global distribution and burden of dengue",
        "Economic and disease burden of dengue in Southeast Asia",
        "Changing epidemiology of dengue in Asia Pacific",
        "Dengue case classification",
        "Dengue: an overview",
        "Dengue vector control: assessing what works?",
        "Prospects for the development of a dengue vaccine",
        "Dengue vaccine",
        "Dengue vaccines: recent developments, ongoing challenges and current candidates",
        "Latest developments and future directions in dengue vaccines",
        "Next generation dengue vaccines: a review of the preclinical development pipeline",
        "Genetic diversity, phylogenay and evolution of dengue viruses",
        "Pathogenesis of dengue virus infection",
        "Dengue virus virulence and diseases severity",
        "Pathogenesis of dengue shock syndrome: immune enhancement or viral virulence",
        "Production of immunity to dengue with virus modified by propagation in mice",
        "Clinical and serological response of man to immunization with attenuated dengue and yellow fever viruses",
        "Immunization with a live attenuated dengue-2-virus candidate vaccine (16681)-PDK 53; clinical, immunological and biological responses to adult volunteers",
        "Study of bivalent dengue vaccine in volunteers",
        "Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti",
        "Tested of dengue2 live-attenuated vaccine (strain 16681 PDK 53) in 10 American volunteers",
        "Dengue virus-specific memory T cell responses in human volunteers receiving a live-attenuated dengue virus type 2 candidate vaccine",
        "Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: a phase Ib randomized study",
        "History of Mahidol dengue vaccine",
        "Dengue vaccine. WHO position paper-July 2016",
        "Current status and future prospects of yellow fever vaccines",
        "Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children aged 2 to 14 years in Asia: a phase III randomized observer-masked, placebo-controlled trial",
        "Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year old",
        "Efficacy of a tetravalent dengue vaccine in children in Latin America",
        "Symptomatic dengue in children in 10 Asian and Latin American countries",
        "Efficacy and long-term safety of a dengue vaccine in region of endemic disease",
        "I randomized study of a tetravalent dengue purified inactivated vaccine in healthy adults in the United States",
        "Induction of neutralizing antibody response against four dengue vaccines in mice by intramuscular electroporation of tetravalent DNA vaccines",
        "ADVASC\u2013new regional initiative supporting transition from dengue vaccine to vaccination in Southeast Asia",
        "Dengue vaccine",
        "Effect of dengue serostatus on dengue vaccine safety and efficacy",
        "Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine",
        "Tetravalent dengue vaccine reduces symptomatic and asymptomatic dengue infections in healthy children and adolescents aged 2-16 years in Asia and Latin America",
        "Dengue vaccine: WHO position paper-September 2018",
        "Pre-vaccination screening strategies for the use of the CYD-TDV dengue vaccine: a meeting report",
        "The potential impact of dengue vaccination with, and without, pre-vaccination screening",
        "Efficacy of a tetravalent dengue vaccine in healthy children and adolescents",
        "Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine. What makes this vaccine different from the Sanofi Pasteur CYDTM vaccine?",
        "T cell immunity to dengue virus and implications for vaccine design"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "@id": "60028190",
        "affilname": "Chulalongkorn University",
        "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
        "affiliation-country": "Thailand"
    },
    "funding": []
}